Velimir A. Luketic
0000-0002-0256-1456
Publication & Citation Trends
Publications
273 total
Impact of Alkaline Phosphatase Normalization on Complication-Free Survival in Primary Biliary Cholangitis.
Cited by 0
Semantic Scholar
OS-089 Elafibranor for primary sclerosing cholangitis: the ELMWOOD phase II randomised controlled trial
Cited by 1
Semantic Scholar
Su2006: METABOLOMIC CHANGES AND DONOR ENGRAFTMENT ARE ASSOCIATED WITH REDUCED RECURRENCE OF HEPATIC ENCEPHALOPATHY AFTER FECAL MICROBIOTA TRANSPLANT: THEMATIC RCT ANALYSIS
Cited by 0
Semantic Scholar
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial.
Cited by 10
Semantic Scholar
GS-001 Thematic trial: phase 2 dose-ranging randomized clinical trial of capsular or enema fecal microbiota transplant to prevent hepatic encephalopathy in cirrhosis already on Rifaximin and Lactulose
Cited by 1
Semantic Scholar
Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study OA
Cited by 2
Semantic Scholar
Utility of Lille Score in Predicting 30-Day Survival in Steroid-Treated Alcohol-Associated Hepatitis OA
Cited by 3
Semantic Scholar
Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD OA
Cited by 106
Semantic Scholar
Research Topics
Liver Disease Diagnosis and Treatment
(179)
Liver Disease and Transplantation
(103)
Liver Diseases and Immunity
(78)
Hepatitis C virus research
(71)
Organ Transplantation Techniques and Outcomes
(47)
Affiliations
University of North Carolina at Chapel Hill
Virginia Department of Education
Beth Israel Deaconess Medical Center
Johnson & Johnson (United States)
Harvard University